NEW YORK (GenomeWeb) – Perthera said today that it is collaborating with drugmaker Novartis to identify breast and lung cancer patients for clinical trials.

Under the collaboration, Novartis will access cancer patients who have used Perthera's Precision Cancer Analysis (PCA) service, which facilitates molecular profiling of patients' cancers. The service includes genomic, proteomic, and phosphoproteomic analyses of patient tumors.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Mar
08
Sponsored by
Swift Biosciences

This webinar will discuss an optimized protocol for methyl-CpG binding domain sequencing (MBD-seq), which enables comprehensive, adequately powered, and cost-effective large-scale methylome-wide association studies (MWAS) of almost all 28 million CpG sites in the genome.

Mar
13

This webinar will share how clinical genetics labs can integrate cytogenetics and molecular data to assess abnormalities using a single sample on a single workflow platform.

Apr
03

Proximity ligation technology generates multi-dimensional next-generation sequencing data that is proving to solve unmet needs in genomic research.